Sign in Subscribe

targeted-therapy

A collection of 17 issues

Liquid biopsy predicts which KRAS G12C patients will benefit from targeted therapy

Skip to content The CRC Digest ◆ TRIAL DATA Liquid biopsy predicts which KRAS G12C patients will benefit from targeted therapy — Journal of Clinical Oncology . This blood-based test could help doctors identify which patients are responding to treatment without waiting for scans. What this means If you have a KRAS G12C

Baseline ctDNA profiling informs HER2-targeted therapy outcomes

Skip to content The CRC Digest Baseline ctDNA profiling informs HER2-targeted therapy outcomes TRIUMPH/MyPathway analysis shows baseline circulating tumor DNA and prior anti-EGFR therapy affect pertuzumab plus trastuzumab efficacy in HER2-amplified metastatic colorectal cancer. (ESMO Open) This content is informational only and does not constitute medical advice. Always consult

ctDNA clearance as early biomarker in KRAS G12C colorectal cancer

Skip to content The CRC Digest ctDNA clearance as early biomarker in KRAS G12C colorectal cancer Phase 3 CodeBreaK 300 results link circulating tumor DNA clearance to efficacy and prognosis with sotorasib plus panitumumab. (JCO) This content is informational only and does not constitute medical advice. Always consult your oncologist

KRAS G12D-targeted therapy tested in preclinical models

Skip to content The CRC Digest KRAS G12D-targeted therapy tested in preclinical models A nanomedicine delivering a KRAS G12D inhibitor showed promise in laboratory models of metastatic colorectal cancer. (Journal of Controlled Release) This content is informational only and does not constitute medical advice. Always consult your oncologist or care

RAS/BRAF wild-type patients: Maintenance strategies compared

Skip to content The CRC Digest RAS/BRAF wild-type patients: Maintenance strategies compared Three trials pooled data on left-sided, RAS/BRAF wild-type metastatic CRC to compare toxicity profiles of different maintenance approaches. (Journal of the National Cancer Institute) This content is informational only and does not constitute medical advice. Always

CRC Research Finding

Skip to content The CRC Digest ◇ Experimental nanomedicine targets KRAS G12D mutation in metastatic colorectal cancer Preclinical research describes a macrophage-hitchhiking delivery system combining gemcitabine and a KRAS G12D inhibitor that improved drug delivery to lung metastases and triggered immune responses in colorectal cancer models. (Journal of Controlled Release) This

CRC Research Finding

Skip to content The CRC Digest ◆ Updated survival analysis for bevacizumab in metastatic CRC (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com